Our latest publication in Nature Communication
Have a look at our latest publication in Nature Communication about autoantibodies against GPCR! 2018 Naturecommunication https://www.nature.com/articles/s41467-018-07598-9
CellTrend has received the patent for auto-antibodies against VEGF
Vascular endothelial growth factor (VEGF) plays a central role in tumor growth, metastasis and angiogenesis. Various drugs (such as Avastin (R)) interfere tumor growth at this pathway. CellTrend were the first to describe auto-antibodies against VEGF and measures them with an validated ELISA. This discovery enables new strategies for personalization of tumor therapy and may…
CellTrend passed the recertification audit
CellTrends management system fullfills the requirement for the ISO 13485 standards.
CellTrend received the Patent for DIAGNOSIS OF CANCER BY DETECTING AUTO-ANTIBODIES AGAINST EGF-RECEPTOR
The results of the present Examples show that anti-EGFR antibody levels are significant lower in patients with ovarian cancer compared to healthy controls. Furthermore, the levels are significantly higher in patients in which show no relapse after treatment with chemotherapeutic agents or an inhibitor of EGFR activity. Levels of anti-EGFR antibody in patients suffering from…
CellTrend received the European patent for antibodies against EGF (EP 3102945)
The results of the present examples show that anti-EGF antibody levels are significantly lower in patients with ovarian cancer compared to healthy controls. In addition, levels are significantly higher in patients who do not relapse after treatment with panitumumab or chemotherapeutic agents. Levels of anti-EGF antibodies in samples are a well-suited predictor of response to…
2nd Symposium on Regulatory Autoantibodies Targeting GPCRs
The 2nd Symposium on Regulatory Autoantibodies Targeting G-Protein-Coupled Receptors takes place from 28th to 30th September 2018 in Lübeck. Internationally renowned scientists give news about GPCRs. We look forward to seeing you there! link to the symposium website
recommendation NINDS
The US National Institute of Neurological Disorders and Stroke (NINDS), one of the most renowned neuroscience research institutes, has included our antibody determinations in its recommendations for the diagnosis of CFS / ME. F2765_Laboratory_Tests_Immune_Module.pdf (291,0 KiB)
Alzheimer’s Disease research
Dr. Lasse Giil et al., Haraldsplass Hospital Bergen, describes the association between multiple antibodies an neuropsychiatric symptoms and Mortality in Alzheimer’s patients. https://www.ncbi.nlm.nih.gov/pubmed/29914018